Roche scraps two Ionis-partnered Huntington’s drugs
BioPharma Dive
The Swiss pharmaceutical giant told patient groups tominersen didn't delay disease progression in one trial, while a study of a second drug was scrapped because of a safety signal in animal testing.
pharminent
July 9, 2026 (Last updated: July 10, 2026)
BioPharma Dive
The Swiss pharmaceutical giant told patient groups tominersen didn’t delay disease progression in one trial, while a study of a second drug was scrapped because of a safety signal in animal testing.
